Conditions A-Z

Bariatric Pre- and Post-Op Support

GLP-1 therapy is increasingly used before bariatric surgery to optimize candidates and after surgery to manage weight regain. Use is off-lab…

Cardiovascular Risk Reduction

Several GLP-1 RAs carry FDA indications for reducing cardiovascular events. Wegovy received a 2024 SELECT-based indication to reduce MACE in…

2 FDA-approved options

Insulin Resistance

Reduced cellular response to insulin, a precursor to type 2 diabetes. GLP-1 therapy improves insulin sensitivity via weight loss and increti…

Metabolic Syndrome

A cluster of conditions — abdominal obesity, hypertension, dyslipidemia, impaired fasting glucose — that raise T2D and CVD risk. No GLP-1 is…

NAFLD / MASLD (Fatty Liver Disease)

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects 25-30% of US adults. GLP-1 and GLP-1/GIP agonists s…

Obesity / Chronic Weight Management

Obesity (BMI 30+ or 27+ with comorbidity) is recognized as a chronic disease by AMA, WHO, and FDA. GLP-1 therapies produce 15-22% mean weigh…

3 FDA-approved options

Obstructive Sleep Apnea

OSA is breathing interruption during sleep, often driven by obesity. In December 2024, Zepbound became the first FDA-approved drug for moder…

1 FDA-approved option

Prediabetes

Prediabetes (HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dL) affects roughly 1 in 3 US adults. No GLP-1 is FDA-approved for prediabetes alo…

PCOS (Polycystic Ovary Syndrome)

PCOS affects 8-13% of reproductive-age women and frequently involves insulin resistance, obesity, and metabolic dysfunction. GLP-1 therapy i…

Type 2 Diabetes

A chronic metabolic disorder of insulin resistance and elevated blood glucose. GLP-1 receptor agonists are first-line injectables when oral …

3 FDA-approved options